Bristol Myers Squibb (BMY) Change in Inventory (2009 - 2026)
Bristol Myers Squibb (BMY) posted quarterly Change in Inventory of -$14.0 million for Q1 2026, down 108.28% YoY from $169.0 million in Q1 2025, and up 80.28% sequentially from -$71.0 million in Q4 2025.
Bristol Myers Squibb (BMY) Change in Inventory (2009 - 2026) Analysis & Trends
Bristol Myers Squibb has disclosed Change in Inventory across 18 years of filings, most recently posting -$14.0 million for Q1 2026.
- In Q1 2026, Change in Inventory fell 108.28% year-over-year to -$14.0 million; the TTM figure through Mar 2026 stood at $1.0 million (down 99.77% YoY), while the FY2025 annual figure was $184.0 million, down 62.14% from the prior year.
- Change in Inventory advanced to -$14.0 million in Q1 2026, from -$71.0 million in the prior quarter.
- Over the last five years, Change in Inventory for BMY reached as high as $282.0 million in Q1 2023 and fell as low as -$175.0 million in Q4 2024.
- The 5-year median for Change in Inventory is $41.0 million (2022), against an average of $86.8 million.
- Annual changes were most pronounced in 2023 — Change in Inventory jumped 28300.0% — and 2024, when it tumbled 188.83%.
- A 5-year view of Change in Inventory shows it stood at $41.0 million in 2022, then surged by 380.49% to $197.0 million in 2023, then slumped by 188.83% to -$175.0 million in 2024, then jumped by 59.43% to -$71.0 million in 2025, then surged by 80.28% to -$14.0 million in 2026.
- According to Business Quant data, Change in Inventory over the past three periods registered -$14.0 million, -$71.0 million, and $90.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Inventory (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 431.00 Mn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 184.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | - |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | -18.00 Mn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 52.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Bristol Myers Squibb | - | - | 8.07 Bn | -14.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.00 Mn |
| Mar 31, 2026 | -14.00 Mn |
| Dec 31, 2025 | -71.00 Mn |
| Dec 31, 2025 | -71.00 Mn |
| Sep 30, 2025 | 90.00 Mn |
| Sep 30, 2025 | 90.00 Mn |
| Jun 30, 2025 | -4.00 Mn |
| Jun 30, 2025 | -4.00 Mn |
| Mar 31, 2025 | 169.00 Mn |
| Mar 31, 2025 | 169.00 Mn |
| Dec 31, 2024 | -175.00 Mn |
| Dec 31, 2024 | -175.00 Mn |
| Sep 30, 2024 | 218.00 Mn |
| Sep 30, 2024 | 218.00 Mn |
| Jun 30, 2024 | 225.00 Mn |
| Jun 30, 2024 | 225.00 Mn |
| Mar 31, 2024 | 218.00 Mn |
| Mar 31, 2024 | 218.00 Mn |
| Dec 31, 2023 | 197.00 Mn |
| Dec 31, 2023 | 197.00 Mn |